As the fifth most common cause of cancer death in men worldwide, prostate cancer is largely identified in patients who are asymptomatic. For the most part, prostate cancer-related deaths occur as a result of advanced disease, which results from any combination of lymphatic, hematogenous, or contiguous local spread. In spite of early responses to treatment with androgen deprivation therapy, most patients eventually progress to castration-resistant prostate cancer (CRPC). The treatment of patients with metastatic castration-resistant prostate cancer (mCRPC) has seen stepwise improvement since 2002, when it was shown that zoledronic acid could reduce skeletal-related event incidence. Non-metastatic castration-resistant prostate cancer (nmCRPC) is only seen in about 4% to 7% of patients with prostate cancer. Three pivotal trials, SPARTAN, PROSPER, and ARAMIS, have examined treatment strategies for this subgroup of patients.
How much do you know about the presentation, workup, and treatment of mCRPC and nmCRPC? Test your knowledge with this quick quiz.
Medscape © 2020 WebMD, LLC
Any views expressed above are the author's own and do not necessarily reflect the views of WebMD or Medscape.
Cite this: Kyle A. Richards. Fast Five Quiz: Castration-Resistant Prostate Cancer - Medscape - Dec 02, 2020.